Teva Announces Community Partnership with Lighthouse
PHILADELPHIA, Jan. 26 /CSRwire/ – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the U.S. organizations selected as part of Teva’s 2017-18 Community Partnership Program. Now in its fourth year, this exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that support patients and their caregivers and Science, Technology, Engineering and Mathematics (STEM) programs in geographic areas where Teva has a business presence.
“We are excited to partner with organizations that are committed to improving the lives of patients on a daily basis,” said Denise Bradley, Senior Vice President, Global Corporate Reputation. “Working with these inspiring organizations allows us to provide meaningful assistance to patients in need as well as our commitment to ensuring Teva employees can achieve their fullest potential by supporting those patients.”
2017-18 Community Partners:
|Pennsylvania (Greater Philadelphia Area)
||Kansas City Area
|Northern New Jersey/New York City
||Salt Lake City, UT
Click here to learn more about Teva’s 2017-18 Community Partners.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 were $19.7 billion. For more information, visit www.tevapharm.com.
For more information, please contact: